Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients-a preliminary study.
Crohn’s disease
Cytokine expression
Oral biofilm
Periodontitis
Ulcerative colitis
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
22
04
2021
accepted:
19
07
2021
pubmed:
13
8
2021
medline:
9
2
2022
entrez:
12
8
2021
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) has multiple impacts on soft and hard tissues in the oral cavity. The aim of this study was to analyze the expression of cytokines in biofilm samples from patients suffering from IBD and compare them to healthy patients. It was hypothesized that different cytokine expression levels and clinical associations might be drawn. A total of 56 biofilm samples from three different patient cohorts (group 0 = healthy, HC n = 30; group 1 = Crohn's disease, CD, n = 19; group 2 = ulcerative colitis, UC, n = 7) were examined for the expression levels of the cytokine interleukins IL-2, -6, and -10; matrix metalloproteinases 7 and 9; and surface antigens CD90/CD11a by quantitative real-time PCR and according to clinical parameters (plaque index, BOP, PD, DMFT, CAL). Relative gene expression was determined using the ∆∆CT method. The mean BOP values (p = 0.001) and PD (p = 0.000) were significantly higher in the CD group compared to controls. Expression of IL-10 was significantly higher in the CD (p = 0.004) and UC groups (p = 0.022). Expression of MMP-7 was significantly higher in the CD group (p = 0.032). IBD patients treated with TNF inhibitors (p = 0.007) or other immunosuppressants (p = 0.014) showed significant overexpression of IL-10 compared to controls. Different expression levels of IL-10 and MMP-7 were detected in plaque samples from IBD patients. As only BOP was significantly increased, we conclude that no clinical impairment of periodontal tissue occurred in IBD patients. With the worldwide increasing incidence of IBD, it is important to obtain insights into the effects of the disease on the oral cavity. The study was registered (01.09.2020) at the German clinical trial registry (DRKS00022956). The study is registered at the German clinical trial registry (DRKS00022956).
Identifiants
pubmed: 34383142
doi: 10.1007/s00784-021-04093-2
pii: 10.1007/s00784-021-04093-2
pmc: PMC8816497
doi:
Substances chimiques
Inflammation Mediators
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Pagination
1217-1228Subventions
Organisme : Deutsche Forschungsgesellschaft DFG
ID : DFG-SFB/TRR241
Informations de copyright
© 2021. The Author(s).
Références
Schmitt H, Neufert C, Neurath MF, Atreya R (2019) Resolution of Crohn’s disease. Semin Immunopathol 41(6):737–746
pubmed: 31552470
Trikudanathan G, Venkatesh PG, Navaneethan U (2012) Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 72(18):2333–2349
pubmed: 23181971
Piras V, Usai P, Mezzena S, Susnik M, Ideo F, Schirru E et al (2017) Prevalence of apical periodontitis in patients with inflammatory bowel diseases: a retrospective clinical study. J Endod 43(3):389–394
pubmed: 28231978
Papageorgiou SN, Hagner M, Nogueira AV, Franke A, Jager A, Deschner J (2017) Inflammatory bowel disease and oral health: systematic review and a meta-analysis. J Clin Periodontol 44(4):382–393
pubmed: 28117909
Cho JH, Brant SR (2011) Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140(6):1704–1712
pubmed: 21530736
Marks DJ, Rahman FZ, Sewell GW, Segal AW (2010) Crohn’s disease: an immune deficiency state. Clin Rev Allergy Immunol 38(1):20–31
pubmed: 19437144
pmcid: 4568313
Lunney PC, Leong RW (2012) Review article: Ulcerative colitis, smoking and nicotine therapy. Aliment Pharmacol Ther 36(11–12):997–1008
pubmed: 23072629
Aldhous MC, Drummond HE, Anderson N, Baneshi MR, Smith LA, Arnott ID et al (2007) Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol 102(3):589–597
pubmed: 17338737
Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP (2004) Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2(1):41–48
pubmed: 15017631
Tan CX, Brand HS, de Boer NK, Forouzanfar T (2017) Gastrointestinal diseases and their oro-dental manifestations: part 2: ulcerative colitis. Br Dent J 222(1):53–57
pubmed: 28084352
de Vries SAG, Tan CXW, Bouma G, Forouzanfar T, Brand HS, de Boer NK (2018) Salivary function and oral health problems in Crohn’s disease patients. Inflamm Bowel Dis 24(6):1361–1367
pubmed: 29718221
Hajishengallis G (2015) Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol 15(1):30–44
pubmed: 25534621
pmcid: 4276050
Grossner-Schreiber B, Fetter T, Hedderich J, Kocher T, Schreiber S, Jepsen S (2006) Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: a case-control study. J Clin Periodontol 33(7):478–484
pubmed: 16820035
Brito F, de Barros FC, Zaltman C, Carvalho AT, Carneiro AJ, Fischer RG et al (2008) Prevalence of periodontitis and DMFT index in patients with Crohn’s disease and ulcerative colitis. J Clin Periodontol 35(6):555–560
pubmed: 18400026
Yucel-Lindberg T, Bage T (2013) Inflammatory mediators in the pathogenesis of periodontitis. Expert Rev Mol Med 15:e7
pubmed: 23915822
Salvi GE, Brown CE, Fujihashi K, Kiyono H, Smith FW, Beck JD et al (1998) Inflammatory mediators of the terminal dentition in adult and early onset periodontitis. J Periodontal Res 33(4):212–225
pubmed: 9689617
Figueredo CM, Brito F, Barros FC, Menegat JS, Pedreira RR, Fischer RG et al (2011) Expression of cytokines in the gingival crevicular fluid and serum from patients with inflammatory bowel disease and untreated chronic periodontitis. J Periodontal Res 46(1):141–146
pubmed: 20701671
Szczeklik K, Owczarek D, Pytko-Polonczyk J, Kesek B, Mach TH (2012) Proinflammatory cytokines in the saliva of patients with active and non-active Crohn’s disease. Pol Arch Med Wewn 122(5):200–208
pubmed: 22538761
Zhang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J et al (2008) NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 41(2):144–149
pubmed: 18222093
Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F (2005) NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 29(1):42–45
pubmed: 15734216
Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH et al (2010) The human oral microbiome. J Bacteriol 192(19):5002–5017
pubmed: 20656903
pmcid: 2944498
du Teil EM, Gabarrini G, Harmsen HJM, Westra J, van Winkelhoff AJ, van Dijl JM (2019) Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS Microbiol Rev 43(1):1–18
Caselli E, Fabbri C, D’Accolti M, Soffritti I, Bassi C, Mazzacane S et al (2020) Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. BMC Microbiol 20(1):120
pubmed: 32423437
pmcid: 7236360
Seidel CL, Gerlach RG, Wiedemann P, Weider M, Rodrian G, Hader M, et al. Defining metaniches in the oral cavity according to their microbial composition and cytokine profile. Int J Mol Sci. 2020;21(21).
Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S et al (2021) Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol 14:1756284820982802
pubmed: 33505519
pmcid: 7812413
Best WR (2006) Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 12(4):304–310
pubmed: 16633052
Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH (2008) Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 14(12):1660–1666
pubmed: 18623174
Ries J, Agaimy A, Wehrhan F, Baran C, Bolze S, Danzer E, et al. Importance of the PD-1/PD-L1 axis for malignant transformation and risk assessment of oral leukoplakia. Biomedicines. 2021;9(2).
Cieplik F, Zaura E, Brandt BW, Buijs MJ, Buchalla W, Crielaard W et al (2019) Microcosm biofilms cultured from different oral niches in periodontitis patients. J Oral Microbiol 11(1):1551596
pubmed: 30598734
Tan CXW, Brand HS, Kalender B, De Boer NKH, Forouzanfar T, de Visscher J. Dental and periodontal disease in patients with inflammatory bowel disease. Clin Oral Investig. 2021.
Brito F, Zaltman C, Carvalho AT, Fischer RG, Persson R, Gustafsson A et al (2013) Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis. Eur J Gastroenterol Hepatol 25(2):239–245
pubmed: 23060013
Noh MK, Jung M, Kim SH, Lee SR, Park KH, Kim DH et al (2013) Assessment of IL-6, IL-8 and TNF-alpha levels in the gingival tissue of patients with periodontitis. Exp Ther Med 6(3):847–851
pubmed: 24137277
pmcid: 3786859
Mattuella LG, Campagnaro MB, Vargas AE, Xavier LL, Oppermann RV, Chies JA et al (2013) Plasma cytokines levels in aggressive and chronic periodontitis. Acta Odontol Scand 71(3–4):683–688
pubmed: 22943212
Neumann C, Scheffold A, Rutz S (2019) Functions and regulation of T cell-derived interleukin-10. Semin Immunol 44:101344
pubmed: 31727465
Mizoguchi F, Slowikowski K, Wei K, Marshall JL, Rao DA, Chang SK et al (2018) Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun 9(1):789
pubmed: 29476097
pmcid: 5824882
Jakubowska K, Pryczynicz A, Iwanowicz P, Niewinski A, Maciorkowska E, Hapanowicz J et al (2016) Expressions of matrix metalloproteinases (MMP-2, MMP-7, and MMP-9) and their inhibitors (TIMP-1, TIMP-2) in inflammatory bowel diseases. Gastroenterol Res Pract 2016:2456179
pubmed: 27034654
pmcid: 4789560
Ebrahimpour S, Shahbazi M, Khalili A, Tahoori MT, ZavaranHosseini A, Amari A et al (2017) Elevated levels of IL-2 and IL-21 produced by CD4+ T cells in inflammatory bowel disease. J Biol Regul Homeost Agents 31(2):279–287
pubmed: 28685527
Ozawa A, Tada H, Tamai R, Uehara A, Watanabe K, Yamaguchi T et al (2003) Expression of IL-2 receptor beta and gamma chains by human gingival fibroblasts and up-regulation of adhesion to neutrophils in response to IL-2. J Leukoc Biol 74(3):352–359
pubmed: 12949238
Bunaes DF, Mustafa M, Mohamed HG, Lie SA, Leknes KN (2017) The effect of smoking on inflammatory and bone remodeling markers in gingival crevicular fluid and subgingival microbiota following periodontal therapy. J Periodontal Res 52(4):713–724
pubmed: 28306142
Seymour RA (2000) Effects of medications on the periodontal tissues in health and disease. Periodontol 2006(40):120–129
Danese S, Vuitton L, Peyrin-Biroulet L (2015) Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 12(9):537–545
pubmed: 26284562
Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3–25
pubmed: 27660341
Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R et al (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60(5):571–607
pubmed: 21464096
de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL et al (2015) Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm 2015:493012
pubmed: 26339135
pmcid: 4539174
Koga A, Matsui T, Takatsu N, Takada Y, Kishi M, Yano Y et al (2018) Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study. Intest Res 16(2):223–232
pubmed: 29743835
pmcid: 5934595
Zhou G, Yu L, Yang W, Wu W, Fang L, Liu Z (2016) Blockade of PLD2 ameliorates intestinal mucosal inflammation of inflammatory bowel disease. Mediators Inflamm 2016:2543070
pubmed: 27721573
pmcid: 5046040
Danese S (2008) Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis 40(Suppl 2):S225–S228
pubmed: 18598993
Vos AC, Wildenberg ME, Arijs I, Duijvestein M, Verhaar AP, de Hertogh G et al (2012) Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 18(3):401–408
pubmed: 21936028
Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11(8):519–531
pubmed: 21785456
Zhang C, Shu W, Zhou G, Lin J, Chu F, Wu H et al (2018) Anti-TNF-alpha therapy suppresses proinflammatory activities of mucosal neutrophils in inflammatory bowel disease. Mediators Inflamm 2018:3021863
pubmed: 30595666
pmcid: 6282128